Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million.

The FDA’s approval of GSK plc’s GSK Ojjaara for the treatment of intermediate or high-risk MF, including primary MF or secondary MF (post-polycythemia vera and post-essential thrombocythaemia ...

The FDA’s approval of GSK plc’s GSK Ojjaara for the treatment of intermediate or high-risk MF, including primary MF or ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

and polycythemia vera (PV) after long-term treatment (>12 months). IFN-α2 induces sustained major or complete molecular remissions in a subset of PV patients with normalization of the bone marrow ...

The primary endpoint of the study was the proportion ... is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be ...

Polycythemia vera is a type of blood cancer ... Takeda Reacquires Japan Rights The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class ...